SEOUL-SEMICONDUCTOR
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) — On April 28, 2017, Seoul Semiconductor Europe GmbH (“Seoul”) filed a patent infringement claim in Germany at the District Court of Düsseldorf against Mouser Electronic Inc. (“Mouser), a global electronic components distributor, which it accused of selling Everlight LED products.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170524005266/en/
In its complaint, Seoul asserted that Everlight’s Mid-Power LED products are infringing Seoul’s patent rights. Seoul has sought a permanent injunction, damages, and recall and destruction of the allegedly infringing products.
The asserted patent serves to improve the light extraction performance of LED devices by enhancing internal-reflection efficiency, which has been widely used in mid-power and high-power LEDs.
This patent litigation is the second patent infringement litigation by Seoul or its affiliate affecting Everlight’s LED products. In March 2017, Seoul Semiconductor Co., Ltd. filed a patent infringement claim in Germany, accusing high-power LED products manufactured by Everlight as well as other LED manufacturers. These patent litigations underscore Seoul’s commitment to protecting its intellectual property rights against infringement, including products consisting of mid-power LEDs and high-power LEDs.
In addition to Seoul’s patent infringement actions, Everlight has been implicated in other patent infringement lawsuits as described below. Nam Ki-bum, Vice President of the Research Center at Seoul, said, “Several LED companies have grown rapidly in a short period of time despite a lack of valuable patent portfolios, which is like building a castle on quicksand. There is no underlying foundation for the company’s products. Seoul, however, has been investing 10% of its revenue in research and development for many years to develop innovative technology and strengthen our patent portfolio. To support a fair market that respects intellectual property rights, Seoul will continuously monitor and take action against alleged infringers in any countries where infringement occurs.”
* Reference [source: various media news articles]
| Plaintiff | Defendant | Business Relation | Patented Technology | Courts | State | Link | ||||||
| Nichia | WOFI Leuchten | Everlight subsidiary | phosphor | Düsseldorf District Court, Germany | Nichia won the suit in the court of first instance and the court ruled for an injunction |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | REGO-Lighting | Used a white LED tube light product by Everlight subsidiary Zenar | phosphor | Düsseldorf District Court, Germany | On Dec. 5, 2016, the appeals court confirmed patent infringement and ruled in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | phosphor | Düsseldorf District Court, Germany | On Oct. 24, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Tachibana Eletech and E&E Japan | Distributor of blue LEDs manufactured by Everlight in Japan | LED chip | Tokyo District Court, Japan | On Oct. 14, 2016, the court issued an oder ruled for an infringement in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2016 |
||||||
| Nichia | Mouser | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | On Oct. 7, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | LED Package | The U.S. District Court for the Eastern District of Texas | The Federal Circuit affirmed an infringement of Nichia’s patents. |
http://www.nichia.co.jp/en/about_nichia/20
http://www.ledinside.com/news/2017/5/nic |
||||||
| Nichia | EBV Elektronik GmbH & Co. KG and EBV Management GmbH (both “EBV“) | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | Still in progress |
http://www.nichia.co.jp/en/about_nichia http://www.ledinside.com/press/2017/3/nichia _files_patent_infringement_lawsuit_against_ |
||||||
| Nichia | Everlight Electronics (China) and Beijing Ducheng Yiguang Electronic Devices Selling Center | Everlight subsidiary | phosphor | Beijing Intellectual Property Court, China | Still in progress |
http://www.nichia.co.jp/en/about_nichia |
||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | High Power LED | Düsseldorf District Court, Germany | Still in progress | |||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | Mid Power LED | Düsseldorf District Court, Germany | On April 28, 2017, Seoul filed the lawsuit. | |||||||
About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fifth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as Wicop – a simpler structured Package-Free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; Acrich, the world's leading direct AC LED; Acrich MJT multi-junction technology; a proprietary family of high-voltage LEDs; NanoDriver Series – World’s Smallest 24W DC LED Drivers and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs.
For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com
# Trademarks: Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005266/en/
Contact:
Asia
Seoul Semiconductor Co., Ltd
Jake Jung, +82 070.4391.8270
Email:
pr@seoulsemicon.com
or
Europe
Seoul
Semiconductor Europe GmbH
Ariane Heim, +49 (0)89 450 3690-0
Email:
press.eu@seoulsemicon.com
or
North
America
Seoul Semiconductor Inc.
David Cox, +1 (919) 410-9856
Email:
David.cox@seoulsemicon.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom